Related Experiment Video
Updated: Sep 9, 2025
08:21
Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations
Published on: July 21, 2023
1.4K
Polypill Strategies for Cardiovascular Prevention in Older Adults: Evidence, Opportunities, and Implementation
Ryan Cheikhali1, Victoria Maksymiuk1, Sara Elattar1
1Department of Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY, USA.
Drugs & Aging
|September 4, 2025
Summary
The polypill, a fixed-dose combination of cardiovascular medications, simplifies treatment and improves adherence for older adults. Evidence shows it effectively reduces cardiovascular events and enhances cost-effectiveness in geriatric populations.
Area of Science:
- Cardiovascular Medicine
- Geriatric Pharmacology
- Public Health Interventions
Background:
- Cardiovascular disease (CVD) is a leading cause of death in older adults, complicated by multimorbidity and polypharmacy.
- The polypill offers a strategy to improve medication adherence and simplify treatment regimens.
- Older adults present unique challenges in CVD prevention, including frailty and increased sensitivity to adverse drug reactions.
Purpose of the Study:
- To review evidence on polypill efficacy for cardiovascular disease prevention in older adults.
- To assess the impact of polypills on medication adherence and cardiovascular event reduction.
- To identify barriers and facilitators for polypill implementation in geriatric care.
Main Methods:
- Systematic review of landmark clinical trials (TIPS, HOPE-3, PolyIran, SECURE).
- Analysis of real-world data on polypill cost-effectiveness and feasibility.
- Consideration of geriatric-specific factors influencing polypill use.
Main Results:
- Polypills demonstrate significant reductions in blood pressure and lipids.
- Improved medication adherence and prevention of major cardiovascular events are observed.
- Real-world data indicate cost-effectiveness and feasibility across various settings.
Conclusions:
- Polypill-based strategies show promise for improving cardiovascular outcomes in aging populations.
- Addressing implementation barriers and geriatric considerations is crucial for wider adoption.
- Strategic use of polypills can enhance CVD prevention and reduce health disparities globally.
More Related Videos
Related Concept Videos
01:26Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
01:26Coronary Artery Disease IV: Preventive Measures
32
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
32
01:27Peripheral Artery Disease III: Interprofessional Care
29
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
29
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
642
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
642
01:27Coronary Artery Disease V: Interprofessional Care
30
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
30
01:23Atherosclerosis IV: Nursing Management
50
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
50